Clinical Trials

Several clinical trials evaluate potassium chloride across conditions such as vascular function, coronary artery disease, fluid balance, drug interactions, and carpometacarpal joint arthritis. Sponsored by academic institutions and government organizations, these Early Phase 1, Phase 1, and unassigned protocols examine physiological outcomes including the vascular effects of potassium salt substitution in healthy individuals and patients with diabetes. Current trial recruitment statuses include recruiting, active not recruiting, and not yet recruiting.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06359665 Not yet recruiting
Arthritis of Carpometacarpal Joint of Left Thumb|Arthritis of Carpometacarpal Joint of Right Thumb
Brent DeGeorge|University of Virginia
2024-06-01 Phase 1
NCT06194864 Recruiting
Drug Interaction
Emalex Biosciences Inc.|Syneos Health|Cambridge Cognition Ltd
2024-01-18 Phase 1
NCT05970601 Not yet recruiting
Vascular Function|Healthy|Diabetes
Prof. Dr. med. Johannes Stegbauer|Heinrich-Heine University Duesseldorf
2023-08-01 Not Applicable
NCT05775055 Active not recruiting
Fluid Balance Outcomes
Loughborough University|entrinsic bioscience LLC
2023-03-14 Not Applicable
NCT05625490 Recruiting
Coronary Artery Disease
Washington University School of Medicine|National Institutes of Health (NIH)|National Heart Lung and Blood Institute (NHLBI)
2022-11-11 Early Phase 1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Potassium Chloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Potassium chloride dissociates into potassium ions that regulate resting membrane potentials and enzymatic processes via sodium-potassium ATPase activity, thereby modulating cellular excitability and action potential propagation in neuromuscular and cardiovascular cells. Maintaining these intracellular electrolyte gradients preserves cellular homeostasis and vascular reactivity, supporting its clinical evaluation in trials assessing vascular function, fluid balance outcomes, and coronary artery disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.